AOL20 天
How a new FDA-approved drug can — and can’t — help people with Alzheimer’s
So, what’s really going on? In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company ...
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
Independence Blue Cross to exclude coverage for some drugs that get accelerated FDA approval
Independence Blue Cross has instituted an 18-month benefit exclusion on certain drugs that receive accelerated approval from ...
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to ...
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
pharmaphorum1 小时
FDA sets August date for subcutaneous Leqembi decision
To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...
Dallas Innovates4 天
Alpha Cognition Inks $44M Licensing Agreement With China’s CMS for Alpha’s ZUNVEYL ...
The agreement with China Medical System Holdings Limited is for the development, manufacturing, and commercialization of ...
Why Alzheimer’s scientists are rethinking the amyloid hypothesis
Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...
FDA approves new drug for advanced Parkinson’s Disease
Thousands of Americans are diagnosed every year with Parkinson’s Disease. It’s a movement disorder that affects the central ...
pharmaphorum1 天
Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage
which is currently under FDA review. Approval for a monthly IV dose of Leqembi is also being sought. The Alzheimer’s Drug Discovery Foundation (ADDF) also welcomed the approval, saying it would ...
Alzheimer’s Drug Study Yields Mixed Results. Wall Street Still Likes Axsome.
In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...
Axsome to seek approval for Alzheimer's-related agitation drug despite mixed data
Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.